Tarsus Pharmaceuticals IncTARS
Price$75.46

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $606.3M+231.4% YoYTTM through 30 Jun 2026
Net Income -$46.5MTTM through 30 Jun 2026
Free Cash Flow $56MTTM through 30 Jun 2026

Margins

Current
Gross Margin94.2%
EBITDA Margin-7.6%
Operating Margin-3.8%
Net Margin-7.7%

Returns

-13.4%ROE
-7.6%ROA

Balance Sheet Health

Debt / Equity0.21x
Current Ratio3.20x
Net Debt-$131.8Mnet cash position
Cash & Equivalents$204.6M

Quality Metrics

Altman Z-Score8.64
Piotroski F-Score5 / 9
FCF Margin9.2%
Rule of 4026.9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $451.4M
Diluted EPS-$1.07TTM
'20'21'22'23'24'25
FY2025: $-1.59

Dividend

No dividend

Capital Allocation

R&D Spend$87.7M
Capex Intensity3.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.